SCHEMBL1924696

SCHEMBL1924696

FC(F)c1cc(-c2ccc(C(F)(F)F)cc2)nc2c(-c3ccncc3)cnn12

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.50
AHR P35869 1/20 0.45
LMNA P02545 1/20 0.44
HSD17B10 Q99714 2/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 2/20 0.41
KIF11 P52732 1/20 0.41
HPGD P15428 5/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
TSHR P16473 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.41
TOP1 P11387 2/20 0.40
POLB P06746 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
USP2 O75604 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926984 0.87 MAPT (0.47) MAPTAHRLMNAHSD17B10KMT2A
SCHEMBL1925330 0.85 MAPT (0.47) MAPTAHRLMNAHSD17B10KMT2A
SCHEMBL1924053 0.84 MAPT (0.65) MAPTAHRLMNAHSD17B10KMT2A
SCHEMBL1925952 0.84 MAPT (0.59) MAPTLMNAHSD17B10KMT2AMEN1
SCHEMBL1346408 0.82 CDK2 (0.49) LMNAHSD17B10KMT2AMEN1HPGD
SCHEMBL312268 0.80 LMNA (0.61) MAPTLMNAHSD17B10KMT2AMEN1
SCHEMBL1348320 0.80 GSK3B (0.47) MAPTLMNAHSD17B10KMT2AMEN1
SCHEMBL1347818 0.76 LMNA (0.44) MAPTLMNAHSD17B10KMT2AMEN1
SCHEMBL311691 0.75 PLAT (0.40) MAPTLMNAHSD17B10HPGDALDH1A1
SCHEMBL1924311 0.75 MAPT (0.63) MAPTHSD17B10KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885AHR 923/4885LMNA 1652/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885AHR 923/4885LMNA 1652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.